Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:COYA NASDAQ:PYXS NASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.75-3.8%$2.60$1.75▼$4.94$104.29M3.222.17 million shs2.31 million shsCOYACoya Therapeutics$4.74+2.2%$4.50$3.71▼$7.75$108.84M0.62133,595 shs114,951 shsPYXSPyxis Oncology$1.76+5.4%$1.84$0.97▼$5.55$105.80M1.42502,299 shs437,524 shsSKYESkye Bioscience$0.79-1.5%$0.80$0.57▼$5.75$28.10M2.95184,402 shs121,810 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-1.62%-13.13%-35.69%-14.15%-23.21%COYACoya Therapeutics+5.22%-4.45%+8.16%+2.43%-17.58%PYXSPyxis Oncology0.00%-2.34%-35.77%+8.44%+30.47%SKYESkye Bioscience+2.50%+3.19%-1.72%+21.08%-63.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.75-3.8%$2.60$1.75▼$4.94$104.29M3.222.17 million shs2.31 million shsCOYACoya Therapeutics$4.74+2.2%$4.50$3.71▼$7.75$108.84M0.62133,595 shs114,951 shsPYXSPyxis Oncology$1.76+5.4%$1.84$0.97▼$5.55$105.80M1.42502,299 shs437,524 shsSKYESkye Bioscience$0.79-1.5%$0.80$0.57▼$5.75$28.10M2.95184,402 shs121,810 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-1.62%-13.13%-35.69%-14.15%-23.21%COYACoya Therapeutics+5.22%-4.45%+8.16%+2.43%-17.58%PYXSPyxis Oncology0.00%-2.34%-35.77%+8.44%+30.47%SKYESkye Bioscience+2.50%+3.19%-1.72%+21.08%-63.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.73Moderate Buy$10.00471.43% UpsideCOYACoya Therapeutics 2.71Moderate Buy$15.33223.49% UpsidePYXSPyxis Oncology 2.63Moderate Buy$6.83288.26% UpsideSKYESkye Bioscience 2.57Moderate Buy$9.801,144.92% UpsideCurrent Analyst Ratings BreakdownLatest SKYE, PYXS, COYA, and BDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026COYACoya Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.006/5/2026PYXSPyxis Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/5/2026COYACoya Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/5/2026COYACoya Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026PYXSPyxis Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/5/2026PYXSPyxis Oncology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.004/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M1.43$0.51 per share3.45$1.97 per share0.89COYACoya Therapeutics$7.95M13.99N/AN/A$2.06 per share2.30PYXSPyxis Oncology$13.86M8.04N/AN/A$0.86 per share2.05SKYESkye BioscienceN/AN/AN/AN/A$0.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)COYACoya Therapeutics-$21.23M-$1.15N/AN/AN/A-266.10%-55.86%-48.86%8/11/2026 (Estimated)PYXSPyxis Oncology-$79.62M-$1.31N/AN/AN/AN/A-135.60%-85.00%8/13/2026 (Estimated)SKYESkye Bioscience-$55.92M-$1.44N/AN/AN/AN/A-217.27%-162.39%N/ALatest SKYE, PYXS, COYA, and BDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026PYXSPyxis Oncology-$0.35-$0.37-$0.02-$0.37$0.02 millionN/A5/12/2026Q1 2026COYACoya Therapeutics-$0.39-$0.32+$0.07-$0.32$0.15 million$0.25 million5/11/2026Q1 2026SKYESkye Bioscience-$0.29-$0.32-$0.03-$0.32N/AN/A5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/A3/23/2026Q4 2025PYXSPyxis Oncology-$0.35-$0.29+$0.06-$0.29$0.13 million$11.04 million3/16/2026Q4 2025BDTXBlack Diamond Therapeutics-$0.18-$0.14+$0.04-$0.27$9.38 millionN/A3/16/2026Q4 2025COYACoya Therapeutics-$0.08-$0.34-$0.26-$0.34$1.93 million$3.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.468.46COYACoya TherapeuticsN/A15.0215.02PYXSPyxis OncologyN/A2.762.76SKYESkye BioscienceN/A1.781.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%COYACoya Therapeutics39.75%PYXSPyxis Oncology39.07%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics9.29%COYACoya Therapeutics6.10%PYXSPyxis Oncology10.60%SKYESkye Bioscience6.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableCOYACoya Therapeutics623.46 million22.03 millionNot OptionablePYXSPyxis Oncology6063.35 million56.64 millionOptionableSKYESkye Bioscience1135.14 million32.97 millionOptionableSKYE, PYXS, COYA, and BDTX HeadlinesRecent News About These CompaniesSkye Bioscience Expands Authorized Shares After Shareholder ApprovalMay 29, 2026 | tipranks.comSkye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1May 20, 2026 | globenewswire.comSkye Bioscience (SKYE) price target decreased by 11.48% to 7.87May 14, 2026 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)May 14, 2026 | theglobeandmail.comSkye Bioscience, Inc.: Skye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateMay 14, 2026 | finanznachrichten.dePomerantz LLP Files Investor Lawsuit Against Skye Bioscience, Inc. – SKYEMay 13, 2026 | natlawreview.comNSkye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026May 12, 2026 | quiverquant.comQUPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateMay 12, 2026 | globenewswire.comSkye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateMay 11, 2026 | globenewswire.comKuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law FirmApril 22, 2026 | globenewswire.comSkye Bioscience Presenting at GLP-1-Based Therapeutics SummitApril 7, 2026 | globenewswire.comSkye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination DevelopmentApril 2, 2026 | globenewswire.comSkye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...March 11, 2026 | finance.yahoo.comSkye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 11, 2026 | finanznachrichten.deSkye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategyMarch 11, 2026 | msn.comSkye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call TranscriptMarch 10, 2026 | seekingalpha.comSkye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 10, 2026 | globenewswire.comSkye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026March 5, 2026 | globenewswire.comSkye Bioscience CFO DepartsFebruary 20, 2026 | marketwatch.comAnalysts Are Bullish on Top Healthcare Stocks: Doximity (DOCS), Skye Bioscience (SKYE)February 5, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSKYE, PYXS, COYA, and BDTX Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$1.75 -0.07 (-3.85%) Closing price 04:00 PM EasternExtended Trading$1.80 +0.04 (+2.57%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Coya Therapeutics NASDAQ:COYA$4.74 +0.10 (+2.16%) Closing price 04:00 PM EasternExtended Trading$4.66 -0.09 (-1.79%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Pyxis Oncology NASDAQ:PYXS$1.76 +0.09 (+5.39%) Closing price 04:00 PM EasternExtended Trading$1.76 -0.01 (-0.28%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Skye Bioscience NASDAQ:SKYE$0.79 -0.01 (-1.54%) Closing price 04:00 PM EasternExtended Trading$0.78 0.00 (-0.53%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
